ABSTRACT
At present, the global prevalence of Helicobacter pylori (Hp) infection is still high. Although bismuth-containing quadruple regimens are recommended by international consensus and guidelines as a first-line treatment for Hp infection, the compliance is decreasing due to more drugs needed and higher adverse events. In recent years, many studies on eradication regimen containing high-dose proton pump inhibitor (PPI) and amoxicillin, a low-resistance and acid-labile antibiotic, demonstrated that the dual therapy could achieve high eradication rate equivalent to the mainstream fist-line therapies and had the advantages of less adverse events, simpler drug composition and higher compliance. However, there are discrepancies in dosage and frequencies of drugs in dual therapies, and cannot reach a unified regimen. This article reviewed all kinds of the dual therapy regimens, which might be helpful for determining the optimal dosage, frequencies, and treatment course, so as to standardize the dual therapy.
ABSTRACT
Since 2015, the European Society of Gastrointestinal Endoscopy (ESGE), the Japan Gastroenterological Endoscopy Society (JGES), the Digestive Endoscopy Specialized Committee of Chinese Medical Doctor Association Endoscopy Physician Branch, the Asia-Pacific working group and the International Consensus Group have updated the guidelines for acute non-variceal upper gastrointestinal bleeding (ANVUGIB). This article summarized these recently published guidelines and made a systematic comparison from the aspects of pre-endoscopic management, endoscopic management, post-endoscopic management and secondary prophylaxis for providing a reference for standardizing the management process of ANVUGIB.
